Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IBRX vs PVLA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IBRX Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–3 Matrix Metrics)

IBRX Overall Winner 6-Pillar Tally: IBRX 4 – 1 PVLA (1 Tie) Matrix Metrics: IBRX 6 – 3 PVLA

As of Nov 16, 2026, ImmunityBio, Inc. (IBRX) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBRX carries a Unified Composite Score of 53.2/100 (HOLD) at $6.03 (66.7x Forward P/E, -150.2% operating margin), whereas PVLA carries 48.9/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: IBRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile PVLA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IBRX vs PVLA
IBRX NASDAQ Head-to-Head Winner
ImmunityBio, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.03
+0.08% 1D
Market Cap $6.5B
TTM Revenue $183M
Forward P/E 66.7x
Beta / 30D Vol 1.68β · 103% Vol
Unified Composite Score
53.2 / 100 HOLD
Tech 53.0 Fund 59.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.3%), weak momentum, RSI 33
RSI-14: 32.7 · SMA20: $7.83 · SMA50: $8.55
PVLA NASDAQ
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.66β · 75% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 38.0 Fund 52.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.0%) with fading momentum, RSI 47
RSI-14: 47.4 · SMA20: $147.90 · SMA50: $143.31

6-Pillar Scorecard Institutional Category Breakdown (IBRX 4 – 1 PVLA)

Columns: Metric · IBRX · PVLA
1. Valuation Multiples IBRX
Forward P/E 66.7x N/M
Trailing P/E 66.7x N/M
PEG Ratio N/M N/M
EV / Revenue 39.9x N/M
2. Growth & Scale IBRX
Revenue Growth (YoY) +52.3% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $183M N/A
Market Cap $6.5B $2.2B
3. Profitability & Quality IBRX
Gross Margin 98.8% N/A
Operating Margin -150.2% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) 0.0% -63.4%
4. Balance Sheet & Cash Flow PVLA
Cash Generation (TTM) -$297M -$43M
Cash Flow Margin N/A N/A
Net Cash / Leverage $824M Net Debt $193M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IBRX
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 93.0% (16th %ile) 47.9% (2nd %ile)
Put/Call OI Skew 1.05x (Balanced) 3.82x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IBRX (6) vs PVLA (3)
Institutional Metric IBRX PVLA Criterion Row Edge
Market Capitalization
Scale
$6.5B $2.2B Larger Scale IBRX
Trailing P/E Ratio
Valuation
66.7x N/M Lower Multiple IBRX
Forward P/E Ratio
Valuation
66.7x N/M Lower Multiple IBRX
Revenue Growth (YoY)
Growth
+52.3% +0.0% Higher Growth IBRX
Operating Margin (TTM)
Profitability
-150.2% 0.0% Higher Margin PVLA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
0.0% -63.4% Higher ROE IBRX
52-Week Range Position
Momentum
39% ($2–$12) 68% ($72–$180) Stronger Trend PVLA
Beta / 30D Volatility
Risk Regime
1.68β · 103% Vol 1.66β · 75% Vol Lower Realized Risk PVLA
Unified Institutional Score
Composite Signal
53.2 / 100 (HOLD) 48.9 / 100 (HOLD) Higher Composite IBRX
Trailing 12M Revenue (USD)
Operating Scale
$183M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
98.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 39.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$297M ($824M Net Debt) -$43M ($193M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PVLA +54.93 pp
IBRX: -34.37% · PVLA: +20.56%
3M Horizon PVLA +18.38 pp
IBRX: -21.96% · PVLA: -3.58%
6M Horizon PVLA +62.75 pp
IBRX: -24.69% · PVLA: +38.06%
1Y Horizon IBRX +121.09 pp
IBRX: +201.25% · PVLA: +80.16%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IBRX Revenue PVLA Revenue IBRX Op. Margin PVLA Op. Margin Margin Leader
FY2018 $0M $30M -209338.3% -113.1% PVLA
FY2019 $0M $40M -7095.9% -62.2% PVLA
FY2020 $0M $30M -36509.1% -115.7% PVLA
FY2021 $0M $30M -35361.9% -165.0% PVLA
FY2022 $0M $30M -146374.2% -167.8% PVLA
FY2023 $0M $40M -58239.5% -27.7% PVLA
FY2024 $10M N/A -2334.2% N/A IBRX
FY2025 $110M N/A -226.0% N/A IBRX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IBRX BREAKDOWN
26d in phase · OBV DISTRIBUTION
Current IV 93.0%
IV Percentile 16th %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact IBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PVLA CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 47.9%
IV Percentile 2nd %ile
Put/Call OI Skew 3.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IBRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.5B market capitalization and -150.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PVLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IBRX vs PVLA Key Questions & Quantitative Answers

As of Nov 16, 2026, ImmunityBio, Inc. (IBRX) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBRX carries a Unified Composite Score of 53.2/100 (HOLD) at $6.03 (66.7x Forward P/E, -150.2% operating margin), whereas PVLA carries 48.9/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: IBRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile PVLA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IBRX leads the Growth & Scale pillar: IBRX posts +52.3% YoY revenue growth and +0.0% YoY earnings growth on $183M TTM revenue (98.8% gross margin, -150.2% operating margin), compared with PVLA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IBRX cumulative revenue shifted +1000.0% while PVLA shifted +33.3%. In operating R&D and SG&A reinvestment, IBRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PVLA.

IBRX screens cheaper on headline valuation multiples. IBRX trades at 66.7x Forward P/E, 66.7x Trailing P/E, N/M PEG, and 39.9x EV/Revenue (unreported FCF margin), whereas PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IBRX (0.0% ROE) versus PVLA (-63.4% ROE) capital efficiency.

In options market volatility and institutional positioning, IBRX carries 93.0% implied volatility (16th %ile, Compressed (<25th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.68β · 103% Vol realized risk). By comparison, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.